Focused On-demand Library for TBC1 domain family member 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O60343

UPID:

TBCD4_HUMAN

Alternative names:

Akt substrate of 160 kDa

Alternative UPACC:

O60343; A7E2X8; B4DU25; B4E235; B6ETN8; B6ETN9; Q5W0B9; Q68D14

Background:

TBC1 domain family member 4, also known as Akt substrate of 160 kDa, plays a crucial role in cellular processes by acting as a GTPase-activating protein for RAB2A, RAB8A, RAB10, and RAB14. Its involvement in insulin-induced glucose transporter SLC2A4/GLUT4 translocation highlights its significance in glucose uptake mechanisms.

Therapeutic significance:

The protein's association with Type 2 diabetes mellitus 5, a disorder characterized by insulin resistance and metabolic syndrome, underscores its therapeutic potential. Targeting this protein could lead to innovative treatments for managing diabetes and its complications, improving patient outcomes.